The estimated Net Worth of Jacob B. Frieberg is at least $536 Thousand dollars as of 27 January 2022. Jacob Frieberg owns over 90,090 units of Vaccinex Inc stock worth over $535,872 and over the last 6 years Jacob sold VCNX stock worth over $0.
Sign up
Jacob Frieberg VCNX stock SEC Form 4 insiders trading
Jacob has made over 2 trades of the Vaccinex Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Jacob bought 90,090 units of VCNX stock worth $100,000 on 27 January 2022.
The largest trade Jacob's ever made was buying 90,090 units of Vaccinex Inc stock on 27 January 2022 worth over $100,000. On average, Jacob trades about 4,461 units every 25 days since 2019. As of 27 January 2022 Jacob still owns at least 94,510 units of Vaccinex Inc stock.
You can see the complete history of Jacob Frieberg stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jacob Frieberg's mailing address?
Jacob's mailing address filed with the SEC is C/O VACCINEX, INC., 1895 MOUNT HOPE AVENUE, ROCHESTER, NY, 14620.
Insiders trading at Vaccinex Inc
Over the last 6 years, insiders at Vaccinex Inc have traded over $3,161 worth of Vaccinex Inc stock and bought 14,062,785 units worth $29,583,294 . The most active insiders traders include Albertfcmi Parent Co. Fried..., Maurice Zauderer, and Maurice Vaccinex (Rochester.... On average, Vaccinex Inc executives and independent directors trade stock every 61 days with the average trade being worth of $2,417,268. The most recent stock trade was executed by Albertfcmi Parent Co. Fried... on 9 August 2024, trading 100 units of VCNX stock currently worth $451.
What does Vaccinex Inc do?
located in rochester, ny, vaccinex is a privately held, clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines and other biologic products to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. we conduct discovery research in-house and in collaboration with world-class academic institutions and biotechnology companies, and have an experienced in-house drug development management team to advance our pre-clinical and clinical stage biopharmaceutical development programs. our development team is led by seasoned industry veterans with both operational and executive level biopharmaceutical industry experience in therapeutic biologics research, manufacturing, quality assurance, quality control, toxicology, pharmacology, drug regulatory affairs, and clinical affairs. we are committed to innovation in the way we approach drug discovery and develop
What does Vaccinex Inc's logo look like?
Complete history of Jacob Frieberg stock trades at Vaccinex Inc
Vaccinex Inc executives and stock owners
Vaccinex Inc executives and other stock owners filed with the SEC include:
-
Dr. Maurice Zauderer Ph.D.,
Co-Founder, CEO, Pres & Director -
Dr. Ernest S. Smith Ph.D.,
Sr. VP of Research & Chief Scientific Officer -
Scott E. Royer C.F.A., M.B.A.,
Chief Financial Officer -
Dr. John E. Leonard Ph.D.,
Sr. VP of Devel. -
Dr. Elizabeth E. Evans Ph.D.,
COO and Sr. VP of Discovery & Translational Medicine -
Elizabeth E. Evans,
COO and Sr. VP of Discovery & Translational Medicine -
John E. Leonard Ph.D.,
Sr. VP of Devel. -
Dr. Deepak M. Sahasrabudhe,
Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor -
Maurice Vaccinex (Rochester...,
President and CEO -
Jill Sanchez,
Chief Financial Officer -
Albert Vaccinex (Rochester)...,
-
Bala S Manian,
Director -
Jeff Goater,
Director -
Albertfcmi Parent Co. Fried...,
-
Robert Scala,
Chief Commercial Officer -
Jacob B. Frieberg,
Director -
Raymond E. Watkins,
SVP & Chief Operating Officer -
Barbara Yanni,
Director -
Alejandro M. Berlin,
Director -
Inc. Vaccinex,,
Director -
Ernest S. Smith,
SVP, Research & CSO -
John E. Leonard,
SVP, Development -
Scott E. Royer,
Chief Financial Officer -
Strydonck, Gerald E. Van,
Director -
Elizabeth E. Evans,
Chief Operating Officer -
Maurice Zauderer,
President and CEO